Intravenous Cyclophosphamide and Plasmapheresis in Dialysis-Dependent ANCA-Associated Vasculitis | Zendy

Ruth J. Pepper | Zendy; Dimitrios Chanouzas | Zendy; Ruth M. Tarzi | Zendy; Mark A. Little | Zendy; Alina Casian | Zendy; Michael Walsh | Zendy; Charles D. Pusey | Zendy; Lorraine Harper | Zendy; Alan D. Salama | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intravenous Cyclophosphamide and Plasmapheresis in Dialysis-Dependent ANCA-Associated Vasculitis

Author(s) -

Ruth J. Pepper,

Dimitrios Chanouzas,

Ruth M. Tarzi,

Mark A. Little,

Alina Casian,

Michael Walsh,

Charles D. Pusey,

Lorraine Harper,

Alan D. Salama

Publication year - 2012

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.03680412

Subject(s) - medicine , plasmapheresis , dialysis , prednisolone , adverse effect , methylprednisolone , cyclophosphamide , renal function , leukopenia , surgery , gastroenterology , chemotherapy , immunology , antibody

Induction therapy with oral cyclophosphamide (CYP) has been a mainstay of treatment in patients with severe renal failure secondary to ANCA-associated vasculitis (AAV). Recent evidence proposes using pulsed intravenous CYP in less severe disease to minimize adverse events. It is unclear if this can be translated to those with dialysis-dependent renal insufficiency.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research